Peter Hoang has served as the CEO of Virovek since 2024. Prior to Virovek, Hoang served as the CEO of Mongoose Bio, Marker Therapeutics, and TapImmune and as the head of strategy for Bellicum Pharmaceuticals. Previously, Hoang served as managing director of innovations at MD Anderson Cancer Center. Prior to that, Hoang served for 16 years in investment banking, most recently as global head of mergers and acquisitions and head of health-care M&A for CIT Group.